Atrial natriuretic peptide in human essential hypertension

P. K. Zachariah, John C Jr. Burnett, S. G. Ritter, C. G. Strong

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

We measured the circulating levels of atrial natriuretic peptide (ANP) in 62 patients with untreated uncomplicated essential hypertension and in 30 normotensive subjects. In the hypertensive patients, mean systolic and diastolic blood pressures were 148 and 101 mm Hg, respectively, and the mean heart rate was 73 beats/min. ANP concentrations were not elevated in the hypertensive group but were actually decreased slightly over those of the control group (27.4 ± 1.8 pg/ml versus 35.3 ± 2.4 pg/ml [P<0.02]). No relationship was found between ANP levels and diastolic blood pressure, plasma renin activity, urinary sodium excretion, or serum creatinine level. In 8 of the 62 patients with essential hypertension, 6 weeks of treatment with a dihydropyridine calcium channel blocker, nitrendipine, significantly reduced plasma ANP levels from 28.6 ± 4.3 pg/ml to 18.7 ± 1.8 pg/ml (P<0.05). In 17 additional patients treated with the hypotensive agent ketanserin, ANP levels were not significantly reduced after treatment. Thus, this study demonstrates that circulating plasma ANP levels are not increased but are slightly decreased in patients with uncomplicated essential hypertension in comparison with normotensive subjects. Furthermore, antihypertensive treatment with a calcium channel antagonist reduced plasma levels of ANP.

Original languageEnglish (US)
Pages (from-to)782-786
Number of pages5
JournalMayo Clinic Proceedings
Volume62
Issue number9
StatePublished - 1987
Externally publishedYes

Fingerprint

Atrial Natriuretic Factor
Blood Pressure
Calcium Channel Blockers
Nitrendipine
Ketanserin
Essential Hypertension
Renin
Antihypertensive Agents
Creatinine
Therapeutics
Heart Rate
Sodium
Control Groups
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Zachariah, P. K., Burnett, J. C. J., Ritter, S. G., & Strong, C. G. (1987). Atrial natriuretic peptide in human essential hypertension. Mayo Clinic Proceedings, 62(9), 782-786.

Atrial natriuretic peptide in human essential hypertension. / Zachariah, P. K.; Burnett, John C Jr.; Ritter, S. G.; Strong, C. G.

In: Mayo Clinic Proceedings, Vol. 62, No. 9, 1987, p. 782-786.

Research output: Contribution to journalArticle

Zachariah, PK, Burnett, JCJ, Ritter, SG & Strong, CG 1987, 'Atrial natriuretic peptide in human essential hypertension', Mayo Clinic Proceedings, vol. 62, no. 9, pp. 782-786.
Zachariah, P. K. ; Burnett, John C Jr. ; Ritter, S. G. ; Strong, C. G. / Atrial natriuretic peptide in human essential hypertension. In: Mayo Clinic Proceedings. 1987 ; Vol. 62, No. 9. pp. 782-786.
@article{eda266203d09490d9ec8679d96fc7723,
title = "Atrial natriuretic peptide in human essential hypertension",
abstract = "We measured the circulating levels of atrial natriuretic peptide (ANP) in 62 patients with untreated uncomplicated essential hypertension and in 30 normotensive subjects. In the hypertensive patients, mean systolic and diastolic blood pressures were 148 and 101 mm Hg, respectively, and the mean heart rate was 73 beats/min. ANP concentrations were not elevated in the hypertensive group but were actually decreased slightly over those of the control group (27.4 ± 1.8 pg/ml versus 35.3 ± 2.4 pg/ml [P<0.02]). No relationship was found between ANP levels and diastolic blood pressure, plasma renin activity, urinary sodium excretion, or serum creatinine level. In 8 of the 62 patients with essential hypertension, 6 weeks of treatment with a dihydropyridine calcium channel blocker, nitrendipine, significantly reduced plasma ANP levels from 28.6 ± 4.3 pg/ml to 18.7 ± 1.8 pg/ml (P<0.05). In 17 additional patients treated with the hypotensive agent ketanserin, ANP levels were not significantly reduced after treatment. Thus, this study demonstrates that circulating plasma ANP levels are not increased but are slightly decreased in patients with uncomplicated essential hypertension in comparison with normotensive subjects. Furthermore, antihypertensive treatment with a calcium channel antagonist reduced plasma levels of ANP.",
author = "Zachariah, {P. K.} and Burnett, {John C Jr.} and Ritter, {S. G.} and Strong, {C. G.}",
year = "1987",
language = "English (US)",
volume = "62",
pages = "782--786",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "9",

}

TY - JOUR

T1 - Atrial natriuretic peptide in human essential hypertension

AU - Zachariah, P. K.

AU - Burnett, John C Jr.

AU - Ritter, S. G.

AU - Strong, C. G.

PY - 1987

Y1 - 1987

N2 - We measured the circulating levels of atrial natriuretic peptide (ANP) in 62 patients with untreated uncomplicated essential hypertension and in 30 normotensive subjects. In the hypertensive patients, mean systolic and diastolic blood pressures were 148 and 101 mm Hg, respectively, and the mean heart rate was 73 beats/min. ANP concentrations were not elevated in the hypertensive group but were actually decreased slightly over those of the control group (27.4 ± 1.8 pg/ml versus 35.3 ± 2.4 pg/ml [P<0.02]). No relationship was found between ANP levels and diastolic blood pressure, plasma renin activity, urinary sodium excretion, or serum creatinine level. In 8 of the 62 patients with essential hypertension, 6 weeks of treatment with a dihydropyridine calcium channel blocker, nitrendipine, significantly reduced plasma ANP levels from 28.6 ± 4.3 pg/ml to 18.7 ± 1.8 pg/ml (P<0.05). In 17 additional patients treated with the hypotensive agent ketanserin, ANP levels were not significantly reduced after treatment. Thus, this study demonstrates that circulating plasma ANP levels are not increased but are slightly decreased in patients with uncomplicated essential hypertension in comparison with normotensive subjects. Furthermore, antihypertensive treatment with a calcium channel antagonist reduced plasma levels of ANP.

AB - We measured the circulating levels of atrial natriuretic peptide (ANP) in 62 patients with untreated uncomplicated essential hypertension and in 30 normotensive subjects. In the hypertensive patients, mean systolic and diastolic blood pressures were 148 and 101 mm Hg, respectively, and the mean heart rate was 73 beats/min. ANP concentrations were not elevated in the hypertensive group but were actually decreased slightly over those of the control group (27.4 ± 1.8 pg/ml versus 35.3 ± 2.4 pg/ml [P<0.02]). No relationship was found between ANP levels and diastolic blood pressure, plasma renin activity, urinary sodium excretion, or serum creatinine level. In 8 of the 62 patients with essential hypertension, 6 weeks of treatment with a dihydropyridine calcium channel blocker, nitrendipine, significantly reduced plasma ANP levels from 28.6 ± 4.3 pg/ml to 18.7 ± 1.8 pg/ml (P<0.05). In 17 additional patients treated with the hypotensive agent ketanserin, ANP levels were not significantly reduced after treatment. Thus, this study demonstrates that circulating plasma ANP levels are not increased but are slightly decreased in patients with uncomplicated essential hypertension in comparison with normotensive subjects. Furthermore, antihypertensive treatment with a calcium channel antagonist reduced plasma levels of ANP.

UR - http://www.scopus.com/inward/record.url?scp=0023257736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023257736&partnerID=8YFLogxK

M3 - Article

C2 - 2957551

AN - SCOPUS:0023257736

VL - 62

SP - 782

EP - 786

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 9

ER -